New agents for chemoprevention of prostate cancer.

Abstract

The magnitude of the problem of prostate cancer, and the failure of conventional chemotherapy and surgery to effect a marked diminution in the total number of deaths from this disease, now indicate that chemoprevention of prostatic carcinogenesis must be seriously considered. We describe the development of a new system for quantitating the process of prostatic carcinogenesis in an experimental animal, and the use of this system to demonstrate that the retinoid, 4-hydroxyphenylretinamide, the deltanoid, Ro24-5531, and the estrogen analog, tamoxifen, all are effective agents for prevention of experimental prostate cancer.

• Authors: M B Sporn
• Journal: European urology (Eur Urol) Vol. 35 Issue 5-6 Pg. 420-3 ( 1999) ISSN: 0302-2838 [Print] Switzerland
• PMID: 10325499 (Publication Type: Journal Article, Review)

Chemical References

• Anticarcinogenic Agents
• Drugs, Investigational
• Ro 24-5531
• Tamoxifen
• Fenretinide
• Calcitriol

Topics

• Animals
• Anticarcinogenic Agents (administration & dosage)
• Calcitriol (administration & dosage, analogs & derivatives)
• Disease Models, Animal
• Drugs, Investigational (therapeutic use)
• Fenretinide (pharmacology)
• Male
• Neoplasm Staging
• Prostatic Neoplasms (drug therapy, pathology, prevention & control)
• Rats
• Tamoxifen (administration & dosage)
• Treatment Outcome